Ayos Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 2.50 M
as on 16-11-2024
- Company Age 23 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -93.39%
(FY 2023)
- Profit -124.41%
(FY 2023)
- Ebitda 19.28%
(FY 2023)
- Net Worth -21.67%
(FY 2023)
- Total Assets -3.70%
(FY 2023)
About Ayos Sciences
The Corporate was formerly known as Aayur Med Biotech Private Limited. The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Haritwal and Rashmi Haritwal serve as directors at the Company.
- CIN/LLPIN
U33110MH2001PTC133640
- Company No.
133640
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2001
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ayos Sciences Private Limited offer?
Ayos Sciences Private Limited offers a wide range of products and services, including Ayurvedic Powder and Medicinal Herbs, Herb Leaves, Product Packing & Labelling Services, Packaging Solutions.
Who are the key members and board of directors at Ayos Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Haritwal  | Director | 11-Oct-2001 | Current |
| Rashmi Haritwal | Director | 11-Oct-2001 | Current |
Financial Performance and Corporate Structure Insights of Ayos Sciences.
Ayos Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 93.39% decrease. The company also saw a substantial fall in profitability, with a 124.41% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ayos Sciences?
In 2023, Ayos Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Belle Sante Diagnostic And Therapeutic Institute Private LimitedActive 17 years 4 monthsVinod Haritwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ayos Sciences?
Unlock and access historical data on people associated with Ayos Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ayos Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ayos Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
